SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0269881107088441v1
0269881107088441v2
22/4/343    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (13)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Anderson, I.
Right arrow Articles by Tylee, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Anderson, I.
Right arrow Articles by Tylee, A
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Antidepressants
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines

IM Anderson

Senior Lecturer and Honorary Consultant Psychiatrist, Neuroscience and Psychiatry Unit, University of Manchester, UK, ian.anderson{at}manchester.ac.uk

IN Ferrier

Honorary Consultant Psychiatrist, School of Neurology, Neurobiology and Psychiatry, Newcastle University, Royal Victoria Infirmary, Newcastle upon Tyne, UK

RC Baldwin

Manchester Mental Health and Social Care Trust, Manchester Royal Infirmary, UK

PJ Cowen

The Psychopharmacology Research Unit, University Department of Psychiatry, Warneford Hospital, Oxford, UK

L Howard

Department, Institute of Psychiatry, King's College London, De Crespigny Park, London, UK

G Lewis

Academic Unit of Psychiatry, Cotham House, Bristol, UK

K Matthews

Section of Psychiatry and Behavioural Sciences, Division of Pathology and Neuroscience, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK

RH McAllister-Williams

Institute of Neuroscience, Newcastle University, Royal Victoria Infirmary, Newcastle upon Tyne, UK

RC Peveler

University of Southampton, Royal South Hants Hospital, Southampton, UK

J Scott

Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK

A Tylee

NIHR Biomedical Research Centre and Health Services and Population Research Department, Institute of Psychiatry, Kings College London, London, UK

A revision of the 2000 British Association for Psychopharmacology evidence-based guidelines for treating depressive disorders with antidepressants was undertaken to incorporate new evidence and to update the recommendations where appropriate. A consensus meeting involving experts in depressive disorders and their management was held in May 2006. Key areas in treating depression were reviewed, and the strength of evidence and clinical implications were considered. The guidelines were drawn up after extensive feedback from participants and interested parties. A literature review is provided, which identifies the quality of evidence to inform the recommendations, the strength of which are based on the level of evidence. These guidelines cover the nature and detection of depressive disorders, acute treatment with antidepressant drugs, choice of drug versus alternative treatment, practical issues in prescribing and management, next-step treatment, relapse prevention, treatment of relapse, and stopping treatment.

Key Words: antidepressants • depressive disorder • evidence-based guidelines • treatment

This version was published on June 1, 2008

Journal of Psychopharmacology, Vol. 22, No. 4, 343-396 (2008)
DOI: 10.1177/0269881107088441


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
DTBHome page
Management of seasonal affective disorder
DTB, November 1, 2009; 47(11): 128 - 132.
[Abstract] [Full Text] [PDF]


Home page
J PsychopharmacolHome page
D. J Nutt
Prescribing antidepressants post Cipriani et al
J Psychopharmacol, November 1, 2009; 23(8): 865 - 866.
[PDF]


Home page
BMJHome page
M. Moore, H. M. Yuen, N. Dunn, M. A Mullee, J. Maskell, and T. Kendrick
Explaining the rise in antidepressant prescribing: a descriptive study using the general practice research database
BMJ, October 15, 2009; 339(oct15_2): b3999 - b3999.
[Abstract] [Full Text] [PDF]


Home page
J PsychopharmacolHome page
G. Goodwin and Consensus Group of the British Association for Psy
Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology
J Psychopharmacol, June 1, 2009; 23(4): 346 - 388.
[Abstract] [PDF]


Home page
Evid. Based Ment. HealthHome page
S. Hatcher
The STAR*D trial: the 300 lb gorilla is in the room, but does it block all the light?
Evid. Based Ment. Health, November 1, 2008; 11(4): 97 - 99.
[Full Text] [PDF]



Advertisement